This site is intended for healthcare professionals

Imfinzi + tremelimumab + chemotherapy improved progression-free survival and overall survival in POSEIDON phase III trial

Read time: 1 mins
Last updated:10th Sep 2021
Published:10th Sep 2021
Positive results from the POSEIDON Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, when added to platinum-based chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest